Chantix, Champix(varenicline)
Champix, Tyrvaya, Varenicline (varenicline) is a small molecule pharmaceutical. Varenicline was first approved as Chantix on 2006-05-10. It has been approved in Europe to treat tobacco use cessation. The pharmaceutical is active against neuronal acetylcholine receptor subunit alpha-4. In addition, it is known to target neuronal acetylcholine receptor subunit alpha-3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| behavior and behavior mechanisms | D001520 |
Trade Name
FDA
EMA
Tyrvaya, Varenicline (discontinued: Chantix)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Varenicline tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TYRVAYA | Oyster Point Pharma | N-213978 RX | 2021-10-15 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| apo-varenicline | unapproved drug for use in drug shortage | 2023-01-26 |
| chantix | New Drug Application | 2024-04-23 |
| tyrvaya | New Drug Application | 2024-02-12 |
| varenicline | ANDA | 2024-07-16 |
| varenicline tartrate | ANDA | 2024-06-13 |
| varenicline tartrate varenicline tartrate | ANDA | 2023-08-25 |
| varenicline varenicline | ANDA | 2024-09-27 |
| varenicline varenicline tartrate | ANDA | 2024-11-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VARENICLINE TARTRATE, TYRVAYA, OYSTER POINT PHARMA | |||
| 2024-10-15 | NP | ||
HCPCS
No data
Clinical
Clinical Trials
385 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Smoking cessation | D016540 | EFO_0004319 | — | 15 | 20 | 31 | 45 | 42 | 146 |
| Tobacco use disorder | D014029 | — | F17 | 9 | 28 | 24 | 22 | 30 | 102 |
| Smoking | D012907 | EFO_0004318 | — | 4 | 12 | 8 | 12 | 22 | 52 |
| Cigarette smoking | D000073865 | — | — | 7 | 6 | 2 | 6 | 8 | 27 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | 14 | 3 | 2 | 2 | 20 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 7 | 2 | 9 | 1 | 19 |
| Dry eye syndromes | D015352 | — | H04.12 | 1 | 5 | 5 | 5 | — | 15 |
| Tobacco use cessation | D020340 | — | — | — | 5 | 4 | 5 | 3 | 14 |
| Alcohol drinking | D000428 | EFO_0004329 | — | 3 | 10 | 1 | 2 | 1 | 14 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | 1 | 4 | 5 | 5 | — | 14 |
Show 60 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 1 | 1 | — | 2 | 5 |
| Weight gain | D015430 | HP_0004324 | — | 2 | 3 | 1 | — | — | 3 |
| Smoking reduction | D000074264 | — | — | — | — | 1 | — | 2 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | 1 | — | — | 2 |
| Ataxia | D001259 | — | R27.0 | — | 2 | 1 | — | — | 2 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | 2 | 1 | — | — | 2 |
| Harm reduction | D040261 | — | — | — | 1 | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
| Habits | D006184 | — | — | — | 1 | 1 | — | — | 1 |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | — | 5 | — | — | 1 | 6 |
| Cognition | D003071 | EFO_0003925 | — | 1 | 1 | — | — | — | 2 |
| Second primary neoplasms | D016609 | — | — | — | 1 | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | 1 | 1 | — | — | — | 1 |
| Spinocerebellar degenerations | D013132 | — | G11 | — | 1 | — | — | — | 1 |
| Spinocerebellar ataxias | D020754 | HP_0007263 | — | — | 1 | — | — | — | 1 |
| Machado-joseph disease | D017827 | EFO_0004135 | — | — | 1 | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Traumatic stress disorders | D040921 | — | — | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 3 | — | — | — | 2 | 5 |
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | 1 | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | 1 | 2 |
| Squamous cell carcinoma | D002294 | — | — | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 1 | 2 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 2 | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 2 | 2 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | — | 1 | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | — | — | 1 | 1 |
| Thoracic surgical procedures | D019616 | — | — | — | — | — | — | 1 | 1 |
| Health behavior | D015438 | — | — | — | — | — | — | 1 | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 1 | 1 |
| Respiratory tract diseases | D012140 | — | — | — | — | — | — | 1 | 1 |
| Respiration disorders | D012120 | — | J00-J99 | — | — | — | — | 1 | 1 |
| Infarction | D007238 | EFO_0009463 | — | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Varenicline |
| INN | varenicline |
| Description | Varenicline, sold under the brand names Chantix and Champix among others, is a medication used for smoking cessation and for the treatment of dry eye disease. It is a nicotinic receptor partial agonist and a cholinergic agonist. When activated, this receptor releases dopamine in the nucleus accumbens, the brain's reward center, thereby reducing cravings and withdrawal symptoms associated with smoking cessation.
|
| Classification | Small molecule |
| Drug class | nicotinic acetylcholine receptor partial agonists/agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | c1cnc2cc3c(cc2n1)C1CNCC3C1 |
Identifiers
| PDB | — |
| CAS-ID | 249296-44-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1396 |
| ChEBI ID | — |
| PubChem CID | 170361 |
| DrugBank | DB01273 |
| UNII ID | W6HS99O8ZO (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Tyrvaya – Oyster Point Pharma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Chantix – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Varenicline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,080 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
97,199 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use